Advertisement

Breast Cancer: PET/CT Imaging

  • Vasiliki P. Filippi
Chapter

Abstract

PET/CT is a hybrid method that combines anatomical imaging with metabolic information in a single examination. Fluorodeoxyglucose (FDG) is a tracer, analog to glucose, that is mainly used, currently, for PET and PET/CT imaging. The role of FDG PET/CT is complementary to conventional imaging methods. The method has a limited role in the detection of primary breast cancer and locoregional staging. It may be useful in initial staging in patients with advanced disease and in assessment of tumor response to therapy. FDG PET/CT has been shown to be effective in early restaging of patients with breast cancer and is of great importance in patients with elevated tumor markers and negative or equivocal findings on conventional imaging techniques.

Keywords

PET/CT Breast cancer Primary Staging Restaging 

References

  1. 1.
    Kapoor K, McCook B, Torok FS (2004) An introduction to PET-CT imaging. Radiographics 24:523–543CrossRefGoogle Scholar
  2. 2.
    Scheidhauer K, Walter C, Seemann MD (2004) FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging 31(1):70–79CrossRefGoogle Scholar
  3. 3.
    Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A (2006) Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98(3):267–274CrossRefGoogle Scholar
  4. 4.
    Rosen E, Eubank W, Mankoff D (2007) FDG PET, PET/CT and breast cancer imaging. Radiographics 27:S215–S229CrossRefGoogle Scholar
  5. 5.
    Avril N, Sassen S, Roylance R (2009) Response to therapy in breast cancer. J Nucl Med 50:55S–63SCrossRefGoogle Scholar
  6. 6.
    Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R, Danceyg J, Arbuckh S, Gwytheri S, Mooneyg M, Rubinsteing L, Shankarg L, Doddg L, Kaplanj R, Lacombec D, Verweijk J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefGoogle Scholar
  7. 7.
    Isasi C, Moadel R, Blaufox M (2005) A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 90:105–112CrossRefGoogle Scholar
  8. 8.
    Eubank W, Mankoff D, Vessele H, Eary J, Schubert E, Dunnwald L, lindsley S, Grallow J, Austin-Seymour M, Ellis G, Livingston R (2002) Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22:5CrossRefGoogle Scholar
  9. 9.
    Filippi V, Malamitsi J, Vlachou F, Laspas F, Georgiou E, Prassopoulos V, Andreou J (2011) The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun 32(2):85–90CrossRefGoogle Scholar
  10. 10.
    Lee J, Rosen E, Maankoff D (2009) The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1-overview detection, and staging. J Nucl Med 50(4):569–581CrossRefGoogle Scholar
  11. 11.
    Yap S, Seltze M, Schiepers C, Gambhir S, Rao J, Phelps M, Valk P, Czernin J (2001) Impact of whole body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician’s perspective. J Nucl Med 42(9):1334–1337PubMedGoogle Scholar
  12. 12.
    Kenny L, Al-Nahhas A, Aboagye E (2011) Novel PET biomarkers for breast cancer imaging. Nucl Med Commun 32:333–335CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Vasiliki P. Filippi
    • 1
  1. 1.MRI, CT and PET/CT DepartmentsHygeia and Mitera HospitalsMaroussiGreece

Personalised recommendations